selegiline has been researched along with fluvoxamine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Klenk-Majewska, B; Lupina, T; Ossowska, G; Pietrasiewicz, T; Zebrowska-Lupina, I | 1 |
| Anttila, M; Karnani, H; Nyman, L; Pelkonen, O; Salonen, JS; Taavitsainen, P | 1 |
| Inoue, T; Iwamoto, N; Izumi, T; Kato, A; Kitaichi, Y; Koyama, T | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Merrick, EL; Stewart, MT | 1 |
2 review(s) available for selegiline and fluvoxamine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for selegiline and fluvoxamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
ACTH 4-9 analogue facilitates the antiimmobility effect of antidepressants and dopamine agonists in swimming rats.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Dopamine Agonists; Exploratory Behavior; Fear; Fluoxetine; Fluvoxamine; Monoamine Oxidase Inhibitors; Motor Activity; Peptide Fragments; Piribedil; Quinpirole; Rats; Rats, Wistar; Selegiline; Swimming | 1997 |
Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Topics: Amphetamines; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluvoxamine; Humans; Ketoconazole; Methamphetamine; Microsomes, Liver; Mixed Function Oxygenases; Monoamine Oxidase Inhibitors; Selegiline; Theophylline | 2000 |
Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Clorgyline; Dose-Response Relationship, Drug; Drug Synergism; Fluvoxamine; Male; Monoamine Oxidase Inhibitors; Motor Activity; Pargyline; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Serotonin Syndrome | 2006 |
Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Topics: Antidepressive Agents; Citalopram; Cost Control; Cost Sharing; Desvenlafaxine Succinate; Drug Costs; Drug Utilization; Duloxetine Hydrochloride; Fluvoxamine; For-Profit Insurance Plans; Health Care Surveys; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Preferred Provider Organizations; Private Sector; Selegiline; United States; Venlafaxine Hydrochloride | 2015 |